Comparative effectiveness and integrated safety of goserelin sustained-release microspheres versus implants in prostate cancer: a patient-based real-world study and systematic review with meta-analysis - Summary - MDSpire
Advertisement
Comparative effectiveness and integrated safety of goserelin sustained-release microspheres versus implants in prostate cancer: a patient-based real-world study and systematic review with meta-analysis
To evaluate the effectiveness of goserelin sustained-release microspheres versus sustained-release implants for androgen deprivation therapy (ADT) in patients with prostate cancer in a real-world setting, and to compare their safety profiles by integrating evidence from published studies on safety outcomes.
Key Findings:
At day 29, TPSA response rates were 81.8% for microspheres and 95.2% for implants, indicating a significant difference in early response.
At day 85, TPSA response rates were 86.4% for microspheres and 93.0% for implants, meeting the non-inferiority criterion.
Interpretation:
Goserelin sustained-release microspheres demonstrated comparable biochemical activity to sustained-release implants over matched 12-week ADT exposure.
Limitations:
Baseline disease stage differed between groups, with more metastatic disease in the implant group, which may affect the generalizability of the findings.
The sample size for safety evaluation in the real-world cohort was limited.
Conclusion:
Goserelin microspheres are a viable alternative ADT formulation with a manageable safety profile, suggesting potential for broader clinical application.
